Guggenheim Capital LLC Makes New $637,000 Investment in Arcellx, Inc. (NASDAQ:ACLX)

Guggenheim Capital LLC bought a new position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,303 shares of the company's stock, valued at approximately $637,000.

Other large investors have also added to or reduced their stakes in the company. Lord Abbett & CO. LLC raised its position in shares of Arcellx by 2.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company's stock valued at $74,478,000 after purchasing an additional 18,004 shares during the period. Avanza Fonder AB purchased a new position in shares of Arcellx in the fourth quarter valued at about $184,000. KBC Group NV boosted its stake in shares of Arcellx by 37.3% in the fourth quarter. KBC Group NV now owns 1,388 shares of the company's stock worth $106,000 after acquiring an additional 377 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Arcellx by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,466 shares of the company's stock worth $879,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Legato Capital Management LLC raised its stake in Arcellx by 36.1% during the 4th quarter. Legato Capital Management LLC now owns 5,999 shares of the company's stock valued at $460,000 after purchasing an additional 1,591 shares during the period. Hedge funds and other institutional investors own 96.03% of the company's stock.

Arcellx Stock Up 0.4 %

ACLX stock traded up $0.24 during midday trading on Wednesday, hitting $64.95. The company's stock had a trading volume of 305,269 shares, compared to its average volume of 554,529. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37. The company has a 50 day moving average of $64.77 and a two-hundred day moving average of $74.43. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of -91.48 and a beta of 0.33.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. The company had revenue of $15.27 million during the quarter, compared to the consensus estimate of $27.42 million. On average, analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Activity at Arcellx

In related news, insider Rami Elghandour sold 38,300 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $62.02, for a total value of $2,375,366.00. Following the completion of the sale, the insider now owns 149,186 shares in the company, valued at approximately $9,252,515.72. The trade was a 20.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $71.64, for a total value of $107,460.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 55,955 shares of company stock valued at $3,504,758. 6.24% of the stock is owned by corporate insiders.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).